Application of biomarker TSPAN7 in diagnosis and treatment of pancreatic cancer

Through the TSPAN7 gene and its expression products as biomarkers, the problems of early diagnosis and treatment of pancreatic cancer are solved, high sensitivity and specific diagnosis of pancreatic cancer are achieved, and platinum chemotherapy is guided, which improves the survival prognosis of patients.

CN118924918APending Publication Date: 2024-11-12THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411194114.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose and treat pancreatic cancer, especially early diagnosis and recurrent or metastatic pancreatic cancer are not effective for existing treatment options, and lacks sensitivity and specific biomarkers.

Method used

Using the TSPAN7 gene and its expression products as biomarkers, drug compositions are developed to enhance or regulate TSPAN7 expression by detecting the expression level of TSPAN7 in pancreatic cancer tissues, for the diagnosis and treatment of pancreatic cancer, and to guide platinum chemotherapy sensitivity.

Benefits of technology

By detecting TSPAN7 expression levels, predict the sensitivity and specificity of the patient to platinum chemotherapy, provide individualized treatment plans, and improve the survival prognosis of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924918A_ABST
    Figure CN118924918A_ABST
Patent Text Reader

Abstract

The invention discloses application of a biomarker TSPAN7 in diagnosis and treatment of pancreatic cancer, and provides a means for diagnosing the pancreatic cancer, and the means is to detect the expression level of the TSPAN7. Whether a pancreatic cancer patient is sensitive to platinum chemotherapy or not is evaluated by evaluating the expression level of the TSPAN7, and the pancreatic cancer patient with high expression of the TSPAN7 is more sensitive to treatment of cis-platinum.
Need to check novelty before this filing date? Find Prior Art